Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 62 Shanghai 52 Guangzhou 39 Hangzhou 20 Changsha 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines7 MediLink Therapeutics (Suzhou) Co., Ltd.3 Guangzhou Sinogen Pharmaceutical Co., Ltd2 Ascentage Pharma Group Inc.2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd2
Site location
Beijing62 Shanghai52 Guangzhou39 Hangzhou20 Changsha18
All 67 locations
Target enrolment
to

Trials with a site in Guangzhou

39 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
BeOne Medicines
Phase 1
84
Beijing, Chongqing, Fuzhou, Guangzhou, Yichang, Shanghai
2026-04-13
Recruiting
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Changsha, Nanjing, Shanghai
2025-12-11
Recruiting
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
Not yet open
Convalife (Shanghai) Co., Ltd.
Phase 1/2
318
Guangzhou
2025-09-10
Recruiting
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Active, closed
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
50
Guangzhou
2025-06-13
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
60
Guangzhou
2025-05-20
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 1/2
149
Guangzhou
2025-05-09
Recruiting
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors
NCT06716619Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy, Serplulimab Injection
DrugSerplulimab
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
32
Guangzhou
2025-02-13
Recruiting
BeOne Medicines
Phase 1
695
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-01-10
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Zhengzhou, Shanghai, Beijing, Guangzhou
2024-12-27
Recruiting
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
NCT06687070Platinum-resistant Recurrent Ovarian Cancer, Advanced Solid Tumor
DrugAPG -2449
Ascentage Pharma Group Inc.
Phase 1
90
Guangzhou
2024-12-17
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
DrugPembrolizumab
Eli Lilly and Company
Phase 1
460
Beijing, Guangzhou, Shanghai
2024-07-01
Recruiting
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
Recruiting
HC Biopharma Inc.
Phase 1
122
Guangzhou
2024-03-27
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Chengdu, Guangzhou
2024-02-26
Active, closed
Daiichi Sankyo
Phase 1
210
Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong
2024-02-22
Recruiting
Hansoh BioMedical R&D Company
Phase 2
220
Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang
2024-02-06
By invitation
Shenzhen NewDEL Biotech, Co., Ltd
Phase 1
96
Xiamen, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Wu’an
2024-02-04
Recruiting
Chipscreen Biosciences, Ltd.
Phase 1
196
Guangzhou
2024-01-05
Recruiting
Xinlu Wang
Phase 1
20
Guangzhou
2024-01
Recruiting
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
990
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou
2023-09-22
Active, closed
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
NCT06302062Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
DrugsAldesleukin·Serplulimab·Cyclophosphamide
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
23
Guangzhou
2023-06-06
Recruiting
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Chengdu
2023-04-19
Active, closed
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Ha’erbin, Hefei, Jinan
2023-03-15
Recruiting
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Harbin, Changsha, Shanghai, Chengdu
2023-01-16
Recruiting
Broadenbio Ltd., Co.
Phase 1
78
Guangzhou, Zhengzhou
2022-12-29
Active, closed
DualityBio Inc.
Phase 1/2
1,123
Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning
2022-07-19
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
Guangzhou, Zhengzhou
2022-05-25
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Recruiting
Ascentage Pharma Group Inc.
Phase 1/2
95
Guangzhou, Hangzhou, Shanghai
2021-05-26
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
DrugHH2853
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing
2020-09-08
Rows per page Showing 1–39 of 39
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 39 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

31 of the 39 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 6 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 39 studies
PhaseStudiesRecruitingShare
Phase 1191748.7%
Phase 1/2171243.6%
Phase 2327.7%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
BeOne Medicines77
MediLink Therapeutics (Suzhou) Co., Ltd.32
Ascentage Pharma Group Inc.22
Daiichi Sankyo21
Guangzhou FineImmune Biotechnology Co., LTD.22
Guangzhou Sinogen Pharmaceutical Co., Ltd22
Suzhou Zelgen Biopharmaceuticals Co.,Ltd21
Axter Therapeutics (Beijing) Co., Ltd11
Beijing Biostar Pharmaceuticals Co., Ltd.10
Broadenbio Ltd., Co.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.